Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modelingIraj Hosseini, Saroja Ramanujan, Yu‐Waye Chu et al.|npj Systems Biology and Applications|2020Cited by 119
Systems‐based digital twins to help characterize clinical <scp>dose–response</scp> and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in <scp>NHL</scp>Monica Susilo, Iraj Hosseini, Kapil Gadkar et al.|Clinical and Translational Science|2023Cited by 74
gPKPDSim: a SimBiology®-based GUI application for PKPD modeling in drug developmentIraj Hosseini, Kapil Gadkar, Anita Gajjala et al.|Journal of Pharmacokinetics and Pharmacodynamics|2018Cited by 32
gQSPSim: A SimBiology‐Based GUI for Standardized QSP Model Development and ApplicationIraj Hosseini, Kapil Gadkar, Justin Feigelman et al.|CPT Pharmacometrics & Systems Pharmacology|2020Cited by 21
A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc MoleculeIraj Hosseini, Saroja Ramanujan, Brett Fleisher et al.|Pharmaceutics|2024Cited by 4